0000000000015511

AUTHOR

Marta De Antonio

showing 26 related works from this author

Additional file 3: of Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

2018

Table S3. Cox regression analyses for 1-year HF-related hospitalization. A competing risk strategy using the Gray method was adopted, considering death as the competing risk in both univariate and multivariate Cox regression analyses. (DOCX 27 kb)

researchProduct

Circulating monocyte subsets and heart failure prognosis

2018

Altres ajuts: Fundacio' La MARATO' de TV3 (201502 to ABG, 201516), AdvanceCat with the support of ACCIÓ [Catalonia Trade & Investment, Generalitat de Catalunya], Fundació Bancària La Caixa. Monocytes are a heterogeneous population of effector cells with key roles in tissue integrity restoration and maintenance. Here, we explore the association of monocyte subsets and prognosis in patients with ambulatory heart failure (HF). Monocyte subsets were classified as classical (CD14 ++ /CD16 -), intermediate (CD14 ++ /CD16 +), or non-classical (CD14 + /CD16 ++). Percentage distribution and absolute cell count were assessed in each subset, and multivariable Cox regression analyses were performed wit…

Male0301 basic medicineEtiologylcsh:Medicine030204 cardiovascular system & hematologyPathology and Laboratory MedicineMonocytesWhite Blood CellsMathematical and Statistical Techniques0302 clinical medicineAnimal CellsCell MovementRisk FactorsCause of DeathMedicine and Health Scienceslcsh:ScienceCause of deathMultidisciplinaryEjection fractionHeartPrognosismedicine.anatomical_structurePhysical SciencesAmbulatoryCardiologyRegression AnalysisFemaleCellular TypesAnatomyStatistics (Mathematics)Research Articlemedicine.medical_specialtyImmune CellsCD14ImmunologyCell Enumeration TechniquesCardiologyResearch and Analysis MethodsDisease-Free Survival03 medical and health sciencesDiagnostic MedicineInternal medicinemedicineHumansStatistical MethodsAgedProportional Hazards ModelsHeart FailureBlood Cellsbusiness.industryProportional hazards modelMonocytelcsh:RBiology and Life SciencesCell Biologymedicine.disease030104 developmental biologyVentricleHeart failureCardiovascular Anatomylcsh:QbusinessMathematicsEjection FractionPLOS ONE
researchProduct

Additional file 2: of Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

2018

Table S2. Cox regression analyses for 30-day rehospitalization. A competing risk strategy using the Gray method was adopted, considering death as the competing risk in both univariate and multivariate Cox regression analyses. (DOCX 27 kb)

researchProduct

Advanced interatrial block predicts new-onset atrial fibrillation and ischemic stroke in patients with heart failure: The “Bayes' Syndrome-HF” study

2018

Advanced interatrial block (IAB) is characterized by a prolonged (≥120 ms) and bimodal P wave in the inferior leads. The association between advanced IAB and atrial fibrillation (AF) is known as “Bayes' Syndrome”, and there is scarce information about it in heart failure (HF). We examined the prevalence of IAB and whether advanced IAB could predict new-onset AF and/or stroke in HF patients. Methods and results: The prospective observational “Bayes' Syndrome-HF” study included consecutive outpatients with chronic HF. The primary endpoints were new-onset AF, ischemic stroke, and the composite of both. A secondary endpoint included all-cause death alone or in combination with the primary endpo…

Malemedicine.medical_specialtyAll-cause deathEnfermedad cardiovascularAdvanced interatrial blockNew-onset atrial fibrillationHeart failure030204 cardiovascular system & hematologyFibrilación auricularBrain IschemiaElectrocardiography03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicineAtrial FibrillationmedicineClinical endpointHumansInteratrial BlockSinus rhythmProspective Studies030212 general & internal medicineStrokeAgedSistema cardiovascularAged 80 and overHeart FailureProportional hazards modelbusiness.industryAtrial fibrillationInteratrial BlockSyndromeMiddle Agedmedicine.diseaseStrokeHeart failureCardiologyFemaleCardiopatía coronariaObservational studyInfarto de miocardioCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesInternational Journal of Cardiology
researchProduct

Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline

2020

Abstract Background Left ventricular ejection fraction (LVEF) trajectories and functional recovery with current heart failure (HF) management is increasingly recognized. Type 2 diabetes mellitus (T2D) leads to a worse prognosis in HF patients. However, it is unknown whether T2D interferes with LVEF trajectories. The aim of this study was to prospectively assess very long-term (up to 15 years) LVEF trajectories in patients with and without T2D and underlying HF. Methods Ambulatory patients admitted to a multidisciplinary HF clinic were prospectively evaluated by scheduled two-dimensional echocardiography at baseline, 1 year, and then every 2 years afterwards, up to 15 years. Statistical anal…

Malelcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyEjection fractionTime FactorsEtiologyDiabetic CardiomyopathiesEndocrinology Diabetes and MetabolismHeart failureType 2 diabetesVentricular Function LeftVentricular Dysfunction LeftDiabetes mellitusLong-termRisk FactorsInternal medicineDiabetes mellitusDiabetic cardiomyopathymedicineHumansProspective StudiesOriginal InvestigationAngiologyAgedHeart FailureEjection fractionbusiness.industryFollow-upType 2 Diabetes MellitusStroke VolumeMiddle Agedmedicine.diseaseProgression-Free SurvivalDiabetes Mellitus Type 2lcsh:RC666-701Heart failureAmbulatoryDisease ProgressionFemaleCardiology and Cardiovascular Medicinebusiness
researchProduct

Lung ultrasound in outpatients with heart failure: the wet‐to‐dry HF study

2021

The Nancy team is supported by the RHU Fight-HF, a public grant overseen by the French National Research Agency (ANR) as part of the second 'Investissements d'Avenir' programme (reference: ANR-15-RHUS-0004), by the French PIA project 'Lorraine Université d'Excellence' (reference: ANR-15-IDEX-04-LUE), the ANR FOCUS-MR (reference: ANR-15-CE14-0032-01), ERA-CVD EXPERT (reference: ANR-16-ECVD-0002-02), the Contrat de Plan Etat Lorraine IT2MP, and FEDER Lorraine. Aims: In ambulatory patients with chronic heart failure (HF), congestion and decongestion assessment may be challenging. The aim of this study is to assess the value of lung ultrasound (LUS) in outpatients with HF in characterizing deco…

Malemedicine.medical_specialtyHeart failure030204 cardiovascular system & hematologyPulmonary congestion03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInterquartile rangeInternal medicineOutpatientsmedicineHumansDiseases of the circulatory (Cardiovascular) systemDecompensation030212 general & internal medicineLungUltrasonographyHeart FailureLung ultrasoundbusiness.industryHazard ratioOriginal ArticlesPrognosismedicine.diseaseConfidence interval[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good healthLung ultrasoundRC666-701Heart failureAmbulatoryCardiologyOriginal ArticleFemaleCardiology and Cardiovascular MedicinebusinessAfter treatmentESC Heart Failure
researchProduct

Pulmonary hypertension and right ventricular dysfunction in heart failure: prognosis and 15‐year prospective longitudinal trajectories in survivors

2020

Aims Systolic pulmonary artery pressure (SPAP), tricuspid annular plane systolic excursion (TAPSE), and TAPSE/SPAP ratio trajectories are not fully characterized in chronic heart failure (HF). We assessed very long-term longitudinal SPAP, TAPSE and TAPSE/SPAP trajectories in HF patients, and their dynamic changes in outcomes. Methods and results Prospective, consecutive, observational registry of real-life HF patients, performing echocardiography studies at baseline and according to a prospectively structured schedule after 1 year, and then every 2 years, up to 15 years. Pulmonary hypertension (PH) was defined as SPAP ≥40 mmHg; right ventricular dysfunction (RVD) was defined at TAPSE ≤16 mm…

medicine.medical_specialtyLong term follow upHypertension PulmonaryVentricular Dysfunction Right030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinemedicine.arteryInternal medicinemedicineClinical endpointHumansIn patientProspective StudiesSurvivorsHeart Failurebusiness.industryPrognosismedicine.diseasePulmonary hypertensionRight ventricular dysfunctionstomatognathic diseasesHeart failurePulmonary arteryCohortVentricular Function RightCardiologyCardiology and Cardiovascular MedicinebusinessEuropean Journal of Heart Failure
researchProduct

Additional file 3: of Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

2018

Table S3. Cox regression analyses for 1-year HF-related hospitalization. A competing risk strategy using the Gray method was adopted, considering death as the competing risk in both univariate and multivariate Cox regression analyses. (DOCX 27 kb)

researchProduct

Additional file 2: of Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

2018

Table S2. Cox regression analyses for 30-day rehospitalization. A competing risk strategy using the Gray method was adopted, considering death as the competing risk in both univariate and multivariate Cox regression analyses. (DOCX 27 kb)

researchProduct

Additional file 2 of Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional …

2020

Additional file 2: Table S1. Demographic, clinical, and therapeutic characteristics at baseline and treatments during follow-up according to etiology of heart failure and presence of diabetes mellitus. Table S2. Paired wise means data analysis in diabetic patients. Table S3. Causes of death of the studied cohort during the 15-year follow-up, according the presence or absence of diabetes mellitus. Table S4. Multivariable Cox regression analysis for all-cause death and the composite end-point all-cause death or heart failure hospitalization.

researchProduct

Multi-Biomarker Profiling and Recurrent Hospitalizations in Heart Failure.

2016

Altres ajuts: Fundació La Marató de TV3 (no.201502-30), Sociedad Española de Cardiología, Societat Catalana de Cardiologia Despite advances in pharmacologic therapy and devices, patients with heart failure (HF) continue to have significant rehospitalization rates and risk prediction remains challenging. We sought to explore the value of a multi-biomarker panel [including NT-proBNP, high-sensitivity cardiac troponin T (hs-TnT), and ST2] on top of clinical assessment for long-term prediction of recurrent hospitalizations in HF. NT-proBNP, hs-TnT, and ST2 (suppression of tumorigenicity-2) levels were measured in 891 consecutive ambulatory HF patients. The independent association between the mu…

lcsh:Diseases of the circulatory (Cardiovascular) systemPediatricsmedicine.medical_specialtyCrude incidenceheart failureHeart failure030204 cardiovascular system & hematologyCardiovascular Medicine03 medical and health sciences0302 clinical medicineInternal medicineMedicinePharmacologic therapy030212 general & internal medicinehospitalizationsOriginal ResearchHospitalizationsbusiness.industrybiomarkerspredictionmedicine.diseaseST2lcsh:RC666-701NT-proBNPHeart failureAmbulatoryBiomarker (medicine)hs-TnTbusinessCardiology and Cardiovascular MedicinePredictionBiomarkersHs-tntFrontiers in cardiovascular medicine
researchProduct

A bio-clinical approach for prediction of sudden cardiac death in outpatients with heart failure: The ST2-SCD score

2019

Sudden cardiac death (SCD) is one of the main modes of death in heart failure (HF) patients and its prediction remains a real challenge. Our aim was to assess the incidence of SCD at 5 years HF contemporary managed outpatients, and to find a simple prediction model for SCD.SCD was considered any unexpected death, witnessed or not, occurring in a previously stable patient with no evidence of worsening HF or any other cause of death. A competing risk strategy was adopted using the Fine-Gray method of Cox regressions analyses that considered other causes of death as the competing event.The derivation cohort included 744 consecutive outpatients (72% men, age 67.9 ± 12.2 years, left ventricular …

Malemedicine.medical_specialty030204 cardiovascular system & hematologySudden deathSudden cardiac deathCohort Studies03 medical and health sciences0302 clinical medicinePredictive Value of TestsRisk FactorsInternal medicineAmbulatory CaremedicineHumanscardiovascular diseases030212 general & internal medicineAgedCause of deathAged 80 and overHeart FailureUnivariate analysisEjection fractionTroponin Tbusiness.industryIncidence (epidemiology)Middle Agedmedicine.diseaseDeath Sudden CardiacHeart failureCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up StudiesInternational Journal of Cardiology
researchProduct

Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients.

2018

Background Heart failure (HF) is associated with a high rate of readmissions within 30 days post-discharge and in the following year, especially in frail elderly patients. Biomarker data are scarce in this high-risk population. This study assessed the value of early post-discharge circulating levels of ST2, NT-proBNP, CA125, and hs-TnI for predicting 30-day and 1-year outcomes in comorbid frail elderly patients with HF with mainly preserved ejection fraction (HFpEF). Methods Blood samples were obtained at the first visit shortly after discharge (4.9 ± 2 days). The primary endpoint was the composite of all-cause mortality or HF-related rehospitalization at 30 days and at 1 year. All-cause mo…

Malemedicine.medical_specialtyFrail ElderlyPopulationComorbidity030204 cardiovascular system & hematologylcsh:GeriatricsPatient Readmission03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineCause of DeathNatriuretic Peptide BrainClinical endpointmedicineHumans030212 general & internal medicineProspective StudieseducationProspective cohort studyAgedAged 80 and overHeart Failureeducation.field_of_studyPredictive markerSurrogate endpointbusiness.industryHazard ratioMembrane Proteinsmedicine.diseasePrognosisComorbidityPeptide Fragmentslcsh:RC952-954.6CA-125 AntigenBiomarker (medicine)FemaleGeriatrics and GerontologybusinessBiomarkersResearch ArticleFollow-Up Studies
researchProduct

Additional file 1: of Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

2018

Table S1. Correlations between studied biomarkers. Correlation between the different studied biomarkers was performed using Pearson correlation test of log-transformed values of each biomarker. (DOCX 25 kb)

researchProduct

Additional file 1: of Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

2018

Table S1. Correlations between studied biomarkers. Correlation between the different studied biomarkers was performed using Pearson correlation test of log-transformed values of each biomarker. (DOCX 25 kb)

researchProduct

Trends in modes of death in heart failure over the last two decades: less sudden death but cancer deaths on the rise.

2019

AIMS Better management of heart failure (HF) over the past two decades has improved survival, mainly by reducing the incidence of death due to cardiovascular (CV) causes. Deaths due to non-CV causes, particularly cancer, may be increasing. This study explored the modes of death of consecutive patients who attended a HF clinic over 17 years. METHODS AND RESULTS A total of 935 deaths were ascertained from 2002 to 2018 among 1876 patients (mean age 65.8 ± 12.5 years, 75% men, left ventricular ejection fraction < 50%) admitted to our HF clinic. Median follow-up was 4.2 years [1.9-7.8]. Mode of death was curated from patient health records and verified by the Catalan and Spanish health system da…

MalePediatricsmedicine.medical_specialtyManagement of heart failure030204 cardiovascular system & hematologyHealth recordsSudden death03 medical and health sciencesDeath Sudden0302 clinical medicineNeoplasmsmedicineHumansLongitudinal StudiesMortalityLung cancerAgedHeart FailureEjection fractionbusiness.industryIncidence (epidemiology)CancerMiddle Agedmedicine.diseaseSpainHeart failureFemaleCardiology and Cardiovascular MedicinebusinessEuropean journal of heart failureReferences
researchProduct

Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction.

2018

Abstract Background Recent ESC guidelines on heart failure (HF) have introduced a new phenotype based on left ventricular ejection fraction (LVEF), called the mid-range (HFmrEF). This phenotype falls between the classical reduced (HFrEF) and preserved (HFpEF) HF phenotypes. We aimed to characterize the HFmrEF biomarker profile and outcomes. Methods 1069 consecutive ambulatory patients were included in the study (age 66.2 ± 12.8 years); 800 with HFrEF (74.8%), 134 with HFmrEF (12.5%), and 135 with HFpEF (12.5%). We measured serum concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hs-TnT), soluble suppression of tumorigenicity (ST2), galectin-…

Malemedicine.medical_specialtymedicine.drug_classGalectin 3030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineTroponin TInternal medicineNatriuretic Peptide BrainNatriuretic peptidemedicineHumans030212 general & internal medicineSoluble transferrin receptorAgedAged 80 and overHeart FailureEjection fractionbiologyTroponin Tbusiness.industryHazard ratioStroke VolumeStroke volumeMiddle Agedmedicine.diseasePrognosisPeptide FragmentsDeathHeart failureChronic Diseasebiology.proteinCardiologyBiomarker (medicine)FemaleCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up StudiesInternational journal of cardiology
researchProduct

Comorbidities, Fragility, and Quality of Life in Heart Failure Patients With Midrange Ejection Fraction.

2018

Objective: To assess the effects of comorbidities, fragility, and quality of life (QOL) on long-term prognosis in ambulatory patients with heart failure (HF) with midrange left ventricular ejection fraction (HFmrEF), an unexplored area. Patients and Methods: Consecutive patients prospectively evaluated at an HF clinic between August 1, 2001, and December 31, 2015, were retrospectively analyzed on the basis of left ventricular ejection fraction category. We compared patients with HFmrEF (n=185) to those with reduced (HFrEF; n=1058) and preserved (HFpEF; n=162) ejection fraction. Fragility was defined as 1 or more abnormal evaluations on 4 standardized geriatric scales (Barthel Index, Older A…

medicine.medical_specialtylcsh:R5-920Ejection fractionbusiness.industryDepression scaleComorbidity score030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicineFragilityQuality of lifeHeart failureInternal medicineAmbulatoryCardiologyMedicineGeriatric Depression Scale030212 general & internal medicinebusinesslcsh:Medicine (General)Mayo Clinic proceedings. Innovations, qualityoutcomes
researchProduct

Heart failure with preserved ejection fraction infrequently evolves toward a reduced phenotype in long-term survivors: a long-term prospective longit…

2019

Background: Long-term trajectories of left ventricular ejection fraction (LVEF) in heart failure (HF) patients with preserved EF (HFpEF) remain unclear. Our objective was to assess long-term longitudinal trajectories in consecutive HFpEF patients and the prognostic impact of LVEF dynamic changes over time. Methods and Results: Consecutive ambulatory HFpEF patients admitted to a multidisciplinary HF Unit were prospectively evaluated by 2-dimensional echocardiography at baseline and at 1, 3, 5, 7, 9, and 11 years of follow-up. Exclusion criteria were patients having a previous known LVEF &lt;50%, patients undergoing only 1 echocardiogram study, and those with a diagnosis of dilated, noncompa…

medicine.medical_specialtyEjection fractionVentricular functionbusiness.industryFollow up studiesHeart failureInsuficiència cardíacamedicine.disease:Informàtica [Àrees temàtiques de la UPC]Heart failureInternal medicineCardiologymedicinecardiovascular systemcardiovascular diseasesCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusinesscirculatory and respiratory physiology
researchProduct

Additional file 8 of Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional …

2020

Additional file 8: Figure S4. Survival and event-free survival curves related to the presence of diabetes mellitus and to etiology (ischemic vs. non-ischemic). Panel B: Event-free survival curves (composite end-point of all-cause death or HF hospitalizations). Diabetic patients from ischemic etiology (dark purple) showed the worse prognosis, while non-diabetic from non-ischemic etiology (blue) showed the best. Remarkably diabetic patients from non-ischemic etiology (soft orange) showed slightly worse prognosis than non-diabetic patients from ischemic etiology (green).

researchProduct

Additional file 1 of Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional …

2020

Additional file 1: Figure S1. Distribution of the number of echocardiograms performed per patient. Number of echocardiograms per patient ranged from 2 (minimum inclusion criteria) to 9 (patients with all the per protocol pre-specified echocardiograms).

congenital hereditary and neonatal diseases and abnormalitiescardiovascular systemcardiovascular diseasescirculatory and respiratory physiology
researchProduct

Additional file 6 of Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional …

2020

Additional file 6: Figure S3. Loess spline curves of long-term LVEF trajectories based on sex. Panel B: Women. P value for trajectory changes on LVEF &lt;0.001 for both groups. P for comparison between groups (interaction between trajectory changes and diabetes) = 0.14. Shaded regions displayed around curves represent the confidence interval at level = 0.95.

researchProduct

Additional file 5 of Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional …

2020

Additional file 5: Figure S3. Loess spline curves of long-term LVEF trajectories based on sex. Panel A: Men. Diabetic (orange) vs. non-diabetic (blue) patients. P value for trajectory changes on LVEF

cardiovascular systemcardiovascular diseaseshumanitiescirculatory and respiratory physiology
researchProduct

Additional file 3 of Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional …

2020

Additional file 3: Figure S2. Loess spline curves of long-term LVEF trajectories based on heart failure duration. Panel A: Patients with HF duration ≤ 12 months; Diabetic (orange) vs. non-diabetic (blue) patients. P value for trajectory changes on LVEF

cardiovascular systemcardiovascular diseasescirculatory and respiratory physiology
researchProduct

Additional file 4 of Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional …

2020

Additional file 4: Figure S2. Loess spline curves of long-term LVEF trajectories based on heart failure duration. Panel B: Patients with HF duration &gt; 12 months. P value for trajectory changes on LVEF

researchProduct

Additional file 7 of Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional …

2020

Additional file 7: Figure S4. Survival and event-free survival curves related to the presence of diabetes mellitus and to etiology (ischemic vs. non-ischemic). Panel A: All-cause death survival curves.

researchProduct